These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 15269828)

  • 21. Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype.
    Sarkar R; Tetreault R; Gao G; Wang L; Bell P; Chandler R; Wilson JM; Kazazian HH
    Blood; 2004 Feb; 103(4):1253-60. PubMed ID: 14551134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid establishment of a HEK 293 cell line expressing FVIII-BDD using AAV site-specific integration plasmids.
    Liu X; Ping H; Zhang C
    BMC Res Notes; 2014 Sep; 7():626. PubMed ID: 25204455
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complete correction of hemophilia A with adeno-associated viral vectors containing a full-size expression cassette.
    Lu H; Chen L; Wang J; Huack B; Sarkar R; Zhou S; Xu R; Ding Q; Wang X; Wang H; Xiao W
    Hum Gene Ther; 2008 Jun; 19(6):648-54. PubMed ID: 18500941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transfer of the full-length dystrophin-coding sequence into muscle cells by a dual high-capacity hybrid viral vector with site-specific integration ability.
    Gonçalves MA; van Nierop GP; Tijssen MR; Lefesvre P; Knaän-Shanzer S; van der Velde I; van Bekkum DW; Valerio D; de Vries AA
    J Virol; 2005 Mar; 79(5):3146-62. PubMed ID: 15709034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cochlear function and transgene expression in the guinea pig cochlea, using adenovirus- and adeno-associated virus-directed gene transfer.
    Luebke AE; Foster PK; Muller CD; Peel AL
    Hum Gene Ther; 2001 May; 12(7):773-81. PubMed ID: 11339894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term correction of hemorrhagic diathesis in hemophilia A mice by an AAV-delivered hybrid FVIII composed of the human heavy chain and the rat light chain.
    Mao J; Wang Y; Zhang W; Shen Y; Zhang G; Xi W; Wang Q; Ruan Z; Wang J; Xi X
    Front Med; 2022 Aug; 16(4):584-595. PubMed ID: 35038106
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A.
    Brown BD; Shi CX; Powell S; Hurlbut D; Graham FL; Lillicrap D
    Blood; 2004 Feb; 103(3):804-10. PubMed ID: 14512318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice.
    Xu L; Daly T; Gao C; Flotte TR; Song S; Byrne BJ; Sands MS; Parker Ponder K
    Hum Gene Ther; 2001 Mar; 12(5):563-73. PubMed ID: 11268288
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficient adenoviral vector transduction and expression of functional human factor VIII in cultured primary human hepatocytes.
    Andrews JL; Weaver L; Kaleko M; Connelly S
    Haemophilia; 1999 May; 5(3):160-8. PubMed ID: 10444282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo gene delivery and expression of physiological levels of functional human factor VIII in mice.
    Connelly S; Smith TA; Dhir G; Gardner JM; Mehaffey MG; Zaret KS; McClelland A; Kaleko M
    Hum Gene Ther; 1995 Feb; 6(2):185-93. PubMed ID: 7537539
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The canine factor VIII 3'-untranslated region and a concatemeric hepatocyte nuclear factor 1 regulatory element enhance factor VIII transgene expression in vivo.
    Notley C; Killoran A; Cameron C; Wynd K; Hough C; Lillicrap D
    Hum Gene Ther; 2002 Sep; 13(13):1583-93. PubMed ID: 12228013
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of human factor VIII by splicing between dimerized AAV vectors.
    Chao H; Sun L; Bruce A; Xiao X; Walsh CE
    Mol Ther; 2002 Jun; 5(6):716-22. PubMed ID: 12027555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector.
    Recchia A; Parks RJ; Lamartina S; Toniatti C; Pieroni L; Palombo F; Ciliberto G; Graham FL; Cortese R; La Monica N; Colloca S
    Proc Natl Acad Sci U S A; 1999 Mar; 96(6):2615-20. PubMed ID: 10077559
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.
    Chuah MK; Schiedner G; Thorrez L; Brown B; Johnston M; Gillijns V; Hertel S; Van Rooijen N; Lillicrap D; Collen D; VandenDriessche T; Kochanek S
    Blood; 2003 Mar; 101(5):1734-43. PubMed ID: 12406898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced plasma factor VIII activity in mice via cysteine mutation using dual vectors.
    Zhu F; Liu Z; Miao J; Qu H; Chi X
    Sci China Life Sci; 2012 Jun; 55(6):521-6. PubMed ID: 22744182
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Site-specific integration of a transgene mediated by a hybrid adenovirus/adeno-associated virus vector using the Cre/loxP-expression-switching system.
    Ueno T; Matsumura H; Tanaka K; Iwasaki T; Ueno M; Fujinaga K; Asada K; Kato I
    Biochem Biophys Res Commun; 2000 Jul; 273(2):473-8. PubMed ID: 10873630
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genomic stability of self-complementary adeno-associated virus 2 during early stages of transduction in mouse muscle in vivo.
    Ren C; Kumar S; Shaw DR; Ponnazhagan S
    Hum Gene Ther; 2005 Sep; 16(9):1047-57. PubMed ID: 16149903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sustaining expression of B domain-deleted human factor VIII mediated by using lentiviral vectors in NOD/SCID mouse.
    Li YJ; Chen C; Zeng LY; Cao J; Xu KL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Jun; 20(3):658-63. PubMed ID: 22739177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. AAV-based neonatal gene therapy for hemophilia A: long-term correction and avoidance of immune responses in mice.
    Hu C; Lipshutz GS
    Gene Ther; 2012 Dec; 19(12):1166-76. PubMed ID: 22241178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors.
    Sabatino DE; Lange AM; Altynova ES; Sarkar R; Zhou S; Merricks EP; Franck HG; Nichols TC; Arruda VR; Kazazian HH
    Mol Ther; 2011 Mar; 19(3):442-9. PubMed ID: 21081906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.